733.04 USD
-8.88 (-1.2%)
733.04 USD
0 (0%)
Overall REGN gets a fundamental rating of 6 out of 10. We evaluated REGN against 525 industry peers in the Biotechnology industry. REGN gets an excellent profitability rating and is at the same time showing great financial health properties. REGN has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
- In the past year REGN was profitable.
- REGN had a positive operating cash flow in the past year.
- In the past 5 years REGN has always been profitable.
- REGN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- REGN has a better Return On Assets (11.40%) than 94.15% of its industry peers.
- REGN has a Return On Equity of 14.79%. This is amongst the best in the industry. REGN outperforms 94.72% of its industry peers.
- With an excellent Return On Invested Capital value of 8.69%, REGN belongs to the best of the industry, outperforming 94.34% of the companies in the same industry.
- The Average Return On Invested Capital over the past 3 years for REGN is significantly below the industry average of 18.07%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| ROIC | 8.69% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)12.44%
ROIC(5y)18.14%
1.3 Margins
- With an excellent Profit Margin value of 32.13%, REGN belongs to the best of the industry, outperforming 96.23% of the companies in the same industry.
- REGN's Profit Margin has improved in the last couple of years.
- With an excellent Operating Margin value of 27.61%, REGN belongs to the best of the industry, outperforming 96.42% of the companies in the same industry.
- REGN's Operating Margin has declined in the last couple of years.
- REGN's Gross Margin of 86.28% is amongst the best of the industry. REGN outperforms 88.68% of its industry peers.
- REGN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.61% | ||
| PM (TTM) | 32.13% | ||
| GM | 86.28% |
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
2. Health
2.1 Basic Checks
- REGN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- REGN has about the same amout of shares outstanding than it did 1 year ago.
- REGN has less shares outstanding than it did 5 years ago.
- Compared to 1 year ago, REGN has an improved debt to assets ratio.
2.2 Solvency
- REGN has an Altman-Z score of 7.32. This indicates that REGN is financially healthy and has little risk of bankruptcy at the moment.
- REGN has a Altman-Z score of 7.32. This is in the better half of the industry: REGN outperforms 78.11% of its industry peers.
- The Debt to FCF ratio of REGN is 0.70, which is an excellent value as it means it would take REGN, only 0.70 years of fcf income to pay off all of its debts.
- REGN has a better Debt to FCF ratio (0.70) than 94.72% of its industry peers.
- REGN has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
- Looking at the Debt to Equity ratio, with a value of 0.09, REGN is doing worse than 61.70% of the companies in the same industry.
- Even though the debt/equity ratio score it not favorable for REGN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.7 | ||
| Altman-Z | 7.32 |
ROIC/WACC1.01
WACC8.63%
2.3 Liquidity
- REGN has a Current Ratio of 4.06. This indicates that REGN is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 4.06, REGN is in line with its industry, outperforming 49.06% of the companies in the same industry.
- A Quick Ratio of 3.51 indicates that REGN has no problem at all paying its short term obligations.
- REGN has a Quick ratio of 3.51. This is comparable to the rest of the industry: REGN outperforms 43.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.06 | ||
| Quick Ratio | 3.51 |
3. Growth
3.1 Past
- The earnings per share for REGN have decreased by -0.92% in the last year.
- Measured over the past years, REGN shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.12% on average per year.
- Looking at the last year, REGN shows a small growth in Revenue. The Revenue has grown by 2.89% in the last year.
- REGN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.55% yearly.
EPS 1Y (TTM)-0.92%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-5.06%
Revenue 1Y (TTM)2.89%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%0.9%
3.2 Future
- REGN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.62% yearly.
- The Revenue is expected to grow by 6.08% on average over the next years.
EPS Next Y-3.81%
EPS Next 2Y0.46%
EPS Next 3Y6.66%
EPS Next 5Y7.62%
Revenue Next Year0.41%
Revenue Next 2Y3.57%
Revenue Next 3Y5.62%
Revenue Next 5Y6.08%
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 16.29 indicates a correct valuation of REGN.
- Compared to the rest of the industry, the Price/Earnings ratio of REGN indicates a rather cheap valuation: REGN is cheaper than 95.47% of the companies listed in the same industry.
- REGN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.38.
- The Price/Forward Earnings ratio is 15.91, which indicates a correct valuation of REGN.
- Based on the Price/Forward Earnings ratio, REGN is valued cheaper than 95.09% of the companies in the same industry.
- REGN's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 24.29.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.29 | ||
| Fwd PE | 15.91 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, REGN is valued cheaply inside the industry as 94.72% of the companies are valued more expensively.
- 95.47% of the companies in the same industry are more expensive than REGN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.85 | ||
| EV/EBITDA | 14.66 |
4.3 Compensation for Growth
- The excellent profitability rating of REGN may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.24
EPS Next 2Y0.46%
EPS Next 3Y6.66%
5. Dividend
5.1 Amount
- With a yearly dividend of 0.47%, REGN is not a good candidate for dividend investing.
- REGN's Dividend Yield is rather good when compared to the industry average which is at 1.18. REGN pays more dividend than 98.30% of the companies in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.85, REGN's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.47% |
5.2 History
- REGN is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y0.46%
EPS Next 3Y6.66%
733.04
-8.88 (-1.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-28 2025-10-28/bmo
Earnings (Next)01-30 2026-01-30/amc
Inst Owners90.13%
Inst Owner Change-0.04%
Ins Owners1.95%
Ins Owner Change3.45%
Market Cap77.04B
Revenue(TTM)14.25B
Net Income(TTM)4.58B
Analysts79.44
Price Target838.03 (14.32%)
Short Float %2.71%
Short Ratio2.67
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.47% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)35.37%
Min EPS beat(2)20.96%
Max EPS beat(2)49.77%
EPS beat(4)3
Avg EPS beat(4)16.75%
Min EPS beat(4)-8.66%
Max EPS beat(4)49.77%
EPS beat(8)6
Avg EPS beat(8)9.92%
EPS beat(12)10
Avg EPS beat(12)9.47%
EPS beat(16)13
Avg EPS beat(16)8.82%
Revenue beat(2)2
Avg Revenue beat(2)6.19%
Min Revenue beat(2)2.66%
Max Revenue beat(2)9.72%
Revenue beat(4)2
Avg Revenue beat(4)0.54%
Min Revenue beat(4)-9.31%
Max Revenue beat(4)9.72%
Revenue beat(8)4
Avg Revenue beat(8)0.34%
Revenue beat(12)8
Avg Revenue beat(12)1.48%
Revenue beat(16)12
Avg Revenue beat(16)2.04%
PT rev (1m)5.28%
PT rev (3m)12.49%
EPS NQ rev (1m)-0.42%
EPS NQ rev (3m)15.94%
EPS NY rev (1m)-0.1%
EPS NY rev (3m)10.29%
Revenue NQ rev (1m)-0.08%
Revenue NQ rev (3m)4.07%
Revenue NY rev (1m)0.12%
Revenue NY rev (3m)2.47%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.29 | ||
| Fwd PE | 15.91 | ||
| P/S | 5.41 | ||
| P/FCF | 19.85 | ||
| P/OCF | 15.19 | ||
| P/B | 2.49 | ||
| P/tB | 2.6 | ||
| EV/EBITDA | 14.66 |
EPS(TTM)45.01
EY6.14%
EPS(NY)46.06
Fwd EY6.28%
FCF(TTM)36.93
FCFY5.04%
OCF(TTM)48.25
OCFY6.58%
SpS135.56
BVpS294.56
TBVpS281.42
PEG (NY)N/A
PEG (5Y)1.24
Graham Number546.17
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| ROCE | 11.01% | ||
| ROIC | 8.69% | ||
| ROICexc | 11.38% | ||
| ROICexgc | 11.99% | ||
| OM | 27.61% | ||
| PM (TTM) | 32.13% | ||
| GM | 86.28% | ||
| FCFM | 27.24% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)12.44%
ROIC(5y)18.14%
ROICexc(3y)18.09%
ROICexc(5y)25.25%
ROICexgc(3y)19.06%
ROICexgc(5y)25.84%
ROCE(3y)15.75%
ROCE(5y)22.96%
ROICexgc growth 3Y-32.64%
ROICexgc growth 5Y-8.74%
ROICexc growth 3Y-33.7%
ROICexc growth 5Y-9.6%
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
F-Score5
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.7 | ||
| Debt/EBITDA | 0.61 | ||
| Cap/Depr | 226.62% | ||
| Cap/Sales | 8.35% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 113.73% | ||
| Profit Quality | 84.78% | ||
| Current Ratio | 4.06 | ||
| Quick Ratio | 3.51 | ||
| Altman-Z | 7.32 |
F-Score5
WACC8.63%
ROIC/WACC1.01
Cap/Depr(3y)292.07%
Cap/Depr(5y)265.92%
Cap/Sales(3y)8.85%
Cap/Sales(5y)7.44%
Profit Quality(3y)83.76%
Profit Quality(5y)77.83%
High Growth Momentum
Growth
EPS 1Y (TTM)-0.92%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-5.06%
EPS Next Y-3.81%
EPS Next 2Y0.46%
EPS Next 3Y6.66%
EPS Next 5Y7.62%
Revenue 1Y (TTM)2.89%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%0.9%
Revenue Next Year0.41%
Revenue Next 2Y3.57%
Revenue Next 3Y5.62%
Revenue Next 5Y6.08%
EBIT growth 1Y-6.18%
EBIT growth 3Y-22.95%
EBIT growth 5Y9.54%
EBIT Next Year-5.21%
EBIT Next 3Y6.05%
EBIT Next 5Y11.85%
FCF growth 1Y-10.97%
FCF growth 3Y-18.47%
FCF growth 5Y12.09%
OCF growth 1Y-2.93%
OCF growth 3Y-14.54%
OCF growth 5Y12.71%
REGENERON PHARMACEUTICALS / REGN FAQ
Can you provide the ChartMill fundamental rating for REGENERON PHARMACEUTICALS?
ChartMill assigns a fundamental rating of 6 / 10 to REGN.
What is the valuation status of REGENERON PHARMACEUTICALS (REGN) stock?
ChartMill assigns a valuation rating of 6 / 10 to REGENERON PHARMACEUTICALS (REGN). This can be considered as Fairly Valued.
Can you provide the profitability details for REGENERON PHARMACEUTICALS?
REGENERON PHARMACEUTICALS (REGN) has a profitability rating of 8 / 10.
What is the financial health of REGENERON PHARMACEUTICALS (REGN) stock?
The financial health rating of REGENERON PHARMACEUTICALS (REGN) is 8 / 10.